We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.225 | 4.86% | 4.85 | 4.70 | 5.00 | 4.85 | 4.625 | 4.63 | 296,354 | 16:20:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -11.55 | 25.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/5/2022 06:33 | Employees or contractors agents of Cenkos and Hawthorn Financial PR should not be posting on this board without declaring their interest. I am retired and have no financial interest in Eden and it's litany of failure. | ravenna23 | |
12/5/2022 06:29 | Sorry this should have read the Financial Reporting Council FRC, not the FCA. | ravenna23 | |
11/5/2022 21:07 | Sense Receptor@SenseRecept Here is an overview of how every single one of Moderna’s mRNA products either failed or did not come to market prior to “Warp Speed.” This list includes source evidence and studies evincing the dangerous nature of mRNA/lipid nanoparticle technology. | supersonico | |
11/5/2022 14:53 | Forger above, why keep doing for free what ar$eholes would pay you to do? Check ravenna's post from earlier today for contact details. | neutralpov | |
11/5/2022 14:37 | Just above, the lying forger keeps on trolling. Doesn't hold a single share in this diseased pooch, the archetypal Sucker Stock for coprophiliacs.... But consciencelessly encourages suckers to buy it. Approach Investisatrickygame' ===== And the SP's slump is today resumed. | neutralpov | |
11/5/2022 13:41 | ravenna23 11 May '22 - 13:21 - 11820 > Doomsday for Eden, June 30th, the last day they can publish 2021 accounts. Tick tock. Spot on, ravenna! And we know from the FCA's ruling the level to which they may stoop if they think they'll get away with it. The less-idiotic larger PIs will jump ship before the accounts are published. ===== Below, the lying forger keeps on spamming. | neutralpov | |
11/5/2022 13:33 | By 2024 Eden will be bust. | ravenna23 | |
11/5/2022 13:21 | Doomsday for Eden, June 30th, the last day they can publish 2021 accounts. Tick tock. | ravenna23 | |
11/5/2022 13:18 | Tricky! Have you lost the plot, why are you posting stuff from 2021. Try reposting the FCA ruling, or the last set of accounts if you want to give potential investors a true picture of Edens prospects. Do you work for Hawthorn Financial PR? Big volume today, everyone must be reading your posts. | ravenna23 | |
11/5/2022 12:25 | 10/12/2021 Eden's US EPA is scheduled 10/05/2021 "Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and a plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, announces that it has passed a key milestone in the US for the approval of its products, Mevalone® and Cedroz." hxxps://polaris.brig | investingisatrickygame | |
11/5/2022 12:02 | Keep in mind the Bayer / Corteva / Eden 'consolidator' 2024 timeline. EU agencies push back glyphosate assessment to mid-2023 | supersonico | |
11/5/2022 11:17 | Through means miraculous, I can warn any decent ones (like Brucie5, except he's much smarter and stopped being a holder years ago) that TW is preparing a slamming expose on this stock. Sell when you can would appear to be sensible. You can then buy back and get twice or thrice the number. | neutralpov | |
11/5/2022 08:43 | Barge poles have their place but are a blunt tool in complex systems...unable to determine on their own the light at the end of the tunnel or it's intensity. | supersonico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions